# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price ta...
Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2025, Harvard Bioscience, Inc. (the "Company") ente...
Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $19.000 million-$21.000 million vs $21.75 million analyst estimate.
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The ...